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Background: Circulating endothelial progenitor cells (EPCs) reflect endothelial repair capacity and may be a
significant marker for the clinical outcomes of cardiovascular disease. While some high-dose statin treatments may
improve endothelial function, it is not known whether different statins may have similar effects on EPCs.This study
aimed to investigate the potential class effects of different statin treatment including pitavastatin and atorvastatin
on circulating EPCs in clinical setting.
Methods: A pilot prospective, double-blind, randomized study was conducted to evaluate the ordinary dose of
pitavastatin (2 mg daily) or atorvastatin (10 mg daily) treatment for 12 weeks on circulating EPCs in patients with
cardiovascular risk such as hypercholesterolemia and type 2 diabetes mellitus (T2DM). Additional in vitro study was
conducted to clarify the direct effects of both statins on EPCs from the patients.
Results: A total of 26 patients (19 with T2DM) completed the study. While the lipid-lowering effects were similar in
both treatments, the counts of circulating CD34+KDR+EPCs were significantly increased (from 0.021 ± 0.015 to
0.054 ± 0.044% of gated mononuclear cells, P < 0.05) only by pitavastatin treatment. Besides, plasma asymmetric
dimethylarginine level was reduced (from 0.68 ± 0.10 to 0.53 ± 0.12 μmol/L, P < 0.05) by atorvastatin, and plasma
vascular endothelial growth factor (VEGF) level was increased (from 74.33 ± 32.26 to 98.65 ± 46.64 pg/mL, P < 0.05) by
pitavastatin. In the in vitro study, while both statins increased endothelial nitric oxide synthase (eNOS) expression,
only pitavastatin increased the phosphorylation of eNOS in EPCs. Pitavastatin but not atorvastatin ameliorated the
adhesion ability of early EPCs and the migration and tube formation capacities of late EPCs.
Conclusions: While both statins similarly reduced plasma lipids, only pitavastatin increased plasma VEGF level and
circulating EPCs in high-risk patients, which is probably related to the differential pleiotropic effects of different statins.
Trial registration: This trial is registered at ClinicalTrials.gov, NCT01386853.
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Coronary heart disease (CHD) remains the leading cause
of death globally [1]. Elevated low-density lipoprotein
cholesterol (LDL-c) levels play a pivotal role in the
pathogenesis of atherosclerosis and LDL-c–lowering ther-
apy can reduce cardiovascular morbidity and mortality [2].
Statins are the most effective drugs for LDL-c lowering
and exert a number of so-called “pleiotropic” vasculopro-
tective effects including production of nitric oxide (NO) by
the upregulation of endothelial NO synthase (eNOS), im-
provement of endothelial function, and induction of the
expression of angiogenic factors such as vascular endothe-
lial growth factor (VEGF) [3].
Accumulating evidence indicates that clinical treat-
ment of statins may not only markedly reduce plasma
LDL-c levels but also significantly improve the clinical
outcomes of the patients at high risk of atherosclerosis
cardiovascular disease. It has been suggested that both
the LDL-c lowering and the pleiotropic effects may con-
tribute to the clinical benefits of statins [4,5]. There have
been several different statins as a class available for clin-
ical use. Among them, atorvastatin, a potent lipophilic
statin, is most widely used in the world. Though were
shown with additional pleiotropic vasculoprotective ef-
fects, particularly in high dose, the potent statins such
as atorvastatin may cause some unfavorable metabolic
effects including the exacerbation of insulin resistance
[4,6]. On the other hand, pitavastatin, as the latest statin
in the same class available for clinical use, is minimally
metabolized by CYP2C9, which is different from other
statins including simvastatin, lovastatin, fluvastatin and
atorvastatin that are mainly metabolized by CYP 3A4
[7]. However, it was not known whether pitavastatin,
with different drug metabolism, may have similar pleio-
tropic effects in term of direct vascular protection of
other statin such as atorvastatin in clinical settings.
Endothelial progenitor cells (EPCs), as a specific group
of cells generated from bone marrow, have been demon-
strated to maintain endothelial integrity and to generate
new blood vessels. It was further indicated that the levels
of circulating EPCs, by various definitions, could reflect
in vivo endothelial repair capacity [8]. In patients with
increased cardiovascular risk especially hyperipidemia
and type 2 diabetes (T2DM), the circulating EPC count,
as a surrogate marker for vascular function, may be re-
duced and associated with the long-term clinical outcomes
[9-11]. Recent clinical evidence suggest the effects of
different statins on vascular endothelial function as well as
EPCs may vary in different clinical settings [3,12-17],
which might be due to the different metabolic nature of
the statins and/or the different natures of the study co-
horts [3]. Besides, the statin treatment in previous studies
was principally with a relatively high dose (usually 3 to 4
times of the standard dose) for a relatively short duration(usually for 4 weeks or less, only one for 8 weeks). The
long-term clinical effects of statin treatment with an
ordinary dose similar to that used in most daily practice
were not known.
Given the potential variation in pleiotropic vascular
protection effects of different statins in clinical settings,
this study aimed to examine whether long-term treat-
ment with an ordinary dose of two different statins,
atorvastain and pitavastatin, may have different effects
on circulating EPC number and function in a group of
high-risk patients including those with hyperlipidemia and
T2DM. Additional in vitro study was also conducted to
elucidate the potential mechanisms of the direct effects of
different statins on EPCs from the patients.
Materials and methods
Clinical study
Study population and design
We conducted a single-center, double-blinded, random-
ized clinical trial as a substudy of “Efficacy and safety
of pitavastatin and atorvastatin: a 12-week, randomized,
double-blinded, active controlled study in high risk pa-
tients with hyperlipidemia” (registered at ClinicalTrials.
gov, NCT01386853). While the main protocol was
conducted in several different hospitals, this study was a
substudy supplemental to the main study that was only
conducted in one of the hospitals. During a period of
3 months, a series of 34 consecutive patients were
screened and enrolled in a 1:1 ratio to atorvastatin or pita-
vastatin treatment in a medical center in Taipei, Taiwan.
The inclusion criteria included (1) Patient with fasting
LDL-c > 100 mg/dL. (2) Patient with at least one of the fol-
lowing description: (i) CHD (ii) T2DM (iii) patients with
more than 2 risk factors other than LDL-c. Subjects were
excluded on the basis of the following criteria: (1) history
of taking medication known to alter blood lipid profiles;
(2) history of type 1 DM or receiving insulin/insulin ana-
logs; (3) serum triglyceride level > 400 mg/dL; (4) history
of cardiovascular disease diagnosed within 3 months;
(5) renal and liver function impairment. The study ob-
jective is to compare pitavastatin 2 mg versus atorva-
statin 10 mg given once daily for 12 weeks on the effect
of lipid profile and the number of circulating EPCs. This
study was approved by local institute research ethics
committee (VGH IRB No: 2011-09-015IB). All participants
gave written informed consents before entering the study.
Human EPC isolation and flow cytometry
The detailed protocol for celll isolation has been
discribed in our previous studies [18]. In brief, a total of
20 cc of blood was drained from the peripheral veins of
the upper arms in each patients in the morning hours
after an overnight fasting. Total mononoculear cells
(MNCs) were isolated from peripheral blood by density
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Sigma, St. Louis, MO, USA). The cells were dissociated
with cell dissociation buffer and incubated with monoclo-
nal antibodies against human KDR (R&D, Minneapolis,
MN, USA) followed by Allophycocyanin-conjugated sec-
ondary antibody, with the peridinin chlorophyll protein
(PerCP)-labeled monoclonal antibodies against human
CD45 (BD Biosciences, San Jose, CA, USA), with the PE-
conjugated monoclonal antibody against human CD133
(Miltenyi Biotec, Germany), and with FITC-conjugated
monoclonal antibodies against human CD34 (BioLegend,
San Diego, CA, USA) in the dark for 30 minutes. After in-
cubation, cells were fixed in 2% paraformaldehyde and ana-
lyzed by flow cytometry performed using a FACS Vantage
Flow Cytometer (BD Biosciences, San Jose, CA, USA).
Each analysis included 150,000 events, after selection for
CD45-positive cells and exclusion of debris. Gated CD34-
or CD133-positive cells were subsequently examined for
the expression of KDR.
Serum biomarkers
All of the blood samples were obtained after an over-
night fasting. The vascular inflammation, atherosclerosis,
and angiogenesis related biomarkers including high-
sensitive C-reactive protein (hs-CRP), total nitric oxide,
interleukin-10, tumor necrosis factor-α, stromal cell-
derived factor-1α (SDF-1α), and VEGF were analyzed by
Quantikine human ELISA kits (R&D systems, Minneapolis,
MN, USA). The serum level of asymmetric dimethylargi-
nine (ADMA) was also measured by human ELISA kit
(DLD Diagnostika GmbH, Hamburg, Germany). All the
measurements were conducted according to the standard
methods in the operation mannul.
In vitro study
Statins
The atorvastatin was purchased from Sigma-Aldrich
(St. Luis, MO, U.S.A). The pitavastatin was kindly
provided as a gift by Professor Kensuka Egashira in
Fukuoka, Japan.
Cultivation for early and late EPCs
The detailed protocos of the culture for early and late
(outgrowth) EPCs have been discribed in our previous
studies [18,19]. In brief, total mononoculear cells (MNCs)
were isolated from peripheral blood in the study patients
by density gradient centrifugation with Histopaque-1077
(1.077 g/ml; Sigma, St. Louis, MO, USA). The MNCs
(5 × 106) were plated in 2 ml endothelial growth medium
(EGM-2 MV; Cambrex, East Rutherford, NJ, USA), with
supplements on fibronectin-coated 6-well plates. Under
daily observation, after 4 days of culturing, medium was
changed and non-adherent cells were removed; attached
“early EPCs” appeared to be elongated with a spindleshape. A certain number of early EPCs could continue to
grow into colonies of “late (outgrowth) EPCs”, which
emerged 2–4 weeks after the start of MNC culture. The
characteristics of the early and the late EPCs have been
well demonstrated previously [18,19].
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide) assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide) was performed to evaluate the mitochon-
drial activity and viability of either early or late EPCs
from the patients with hypercholesterolemia and T2DM.
After pre-treated with statins for 24 hours, 1 mg/mL of
MTT (Sigma, St. Louis, MO, USA) was added to the
EPC medium culture and incubated for an additional 3–
4 hours. The medium was then removed and the cells
were solubilized in isopropanol. The amount of the dye
released from the cells was measured with a spectro-
photometer at 570 nm and subtracted background at
690 nm. An increase in the number of viable cells results
in an increase in the amount of MTT formed and, there-
fore, in absorbance.
Adhesion assay on early EPCs
The adhesion assay for early EPCs was determined to
elucidate the effect of both statins (10−7 M) on the early
EPCs. The adhesion assay was performed with the
methods as described in detail previously [18,19].
Proliferation assay on late EPCs
The proliferation assay was performed to elucidate the
effect of both statins (10−5 to 10−9 M, for 24 hours) on
late EPCs. The proliferation assay was performed with
the methods as described in detail previously [18,19].
Migration assay on late EPCs
The effect of statins on functional assays of late EPCs
including migration assay and tube formation assay
were examined after pre-treatment of different statins
(10−7 M) for 24 hours. The migratory function of late
EPCs was evaluated by a modified Boyden chamber assay
(Transwell, Coster, San Diego, CA, USA) [19]. Briefly,
isolated EPCs were detached as described above with
trypsin/EDTA and then 1×104 late EPCs were placed in
the upper chambers of 24-well Transwell plates with
polycarbonate membrane (8-mm pores) with serum-
free endothelial growth medium; VEGF (50 ng/ml) in
medium was placed in the lower chamber. After incuba-
tion for 24 hours, the membrane was washed briefly with
PBS and fixed with 4% paraformaldehyde. The membrane
was then stained using hematoxylin solution and carefully
removed. The magnitude of migration of the late EPCs
was evaluated by counting the migrated cells in six random
high-power (100X) microscopic fields.
Table 1 Baseline characteristics of study subjects
Pitavastatin Atorvastatin P value
(n = 13) (n = 13)
Age (years) 60.1 ± 7.3 60.5 ± 10.3 0.90
Male, n (%) 6 (46.2%) 5 (38.5%) 0.69
Type 2 Diabetes Mellitus, n (%) 8 (61.5%) 11 (84.6%) 0.38
Hypertension, n (%) 10 (70.7%) 7 (53.8%) 0.67
Coronary artery disease, n (%) 2 (15.4%) 0 (0.0%) 0.14
Current smoker, n (%) 2 (15.4%) 1 (7.7%) 0.54
Waist Circumference (cm) 87.7 ± 6.3 91.7 ± 13.1 0.33
BMI (kg/m2) 25.2 ± 3.9 27.1 ± 3.8 0.22
SBP (mmHg) 118.2 ± 12.6 127.5 ± 19.6 0.17
DBP (mmHg) 76.2 ± 8.9 80.8 ± 11.1 0.26
HR (/min) 73.5 ± 11.7 75.7 ± 10.9 0.63
Creatinine (μmol/L) 76.9 ± 19.4 70.7 ± 17.7 0.25
ALT (U/L) 21.7 ± 13.5 33.6 ± 21.1 0.10
Glucose (mmo/L) 6.98 ± 1.39 6.28 ± 1.04 0.16
A1c (%) 6.8 ± 1.1 6.3 ± 0.5 0.18
Medication
Metformin, n (%) 8 (61.5%) 11 (84.6%) 0.14
DPP-4 inhibitors, n (%) 2 (15.4%) 1 (7.7%) 0.54
PPAR-γ agonists, n (%) 0 (0%) 1 (7.7%) 0.31
ARB, n (%) 3 (23.1%) 4 (30.8%) 0.66
ACEI, n (%) 3 (23.1%) 2 (15.4%) 0.62
CCB, n (%) 5 (38.5%) 3 (23.1%) 0.40
Beta-blockers, n (%) 2 (15.4%) 2 (15.4%) 1.00
Diuretics, n (%) 1 (7.7%) 4 (30.8%) 0.14
Aspirin, n (%) 3 (23.1%) 1 (7.7%) 0.28
Values are mean ± standard deviation (SD) or number (%). ARB: angiotensin II
receptor blockers; ACEI: angiotensin converting enzyme inhibitors; BMI: body
mass index; CCB: calcium channel blockers; DBP: diastolic blood pressure; HR:
heart beats ALT: analine amiontransferase; DPP-4 inhibitors: dipeptidyl
peptidase-4 inhibitors; PPAR-γ agonists: peroxisome proliferator activator
receptor-gamma agonists, SBP: systolic blood pressure.
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The EPC tube formation assay was performed using the
In Vitro Angiogenesis Assay Kit (Chemicon). ECMatrix
gel solution was thawed overnight at 4°C, mixed with
ECMatrix diluent buffer, and placed in a 96-well plate
for 1 h at 37°C to allow the matrix solution to solidify.
Late EPCs were harvested with trypsin/EDTA, as de-
scribed above, and 1X104 EPCs were placed onto a matrix
with EGM-2 MV medium and incubated at 37°C for 16 h.
Tubule formation was inspected with an inverted light
microscope (100X). Six representative fields were used
to determine the average of the total area of complete
tubes formed by cells using the computer software, Image-
Pro Plus.
Western blot analysis
Early and late EPCs derived from the patients with T2DM
were cultured on the on fibronectin-coated 6-well plates
for examination of endothelial nitric oxide synthase
(eNOS) protein expression determined by Western blot-
ting after the statins exposure. The Western blot analyses
were performed with the methods as described in detail
previously [19].
Statistical analysis
Continuous variables were expressed as mean ± SDs, and
categorical variables were presented as frequencies and per-
centages. Differences between two groups were analyzed
using a two-tailed Student’s t test or one-way analysis of
variance. Given the specific experiment purpose of this clin-
ical study, the changes of the major index parameters were
compared before and after the treatment within the group
by the paired Student’s t test. All tests were two sided and a
value of P < 0.05 was considered statistically significant.
Statistical analysis was adequately performed with SPSS
software (version 18; SPSS Inc., Chicago, Illinos).
Results
Clinical study
Baseline characteristics of the study patients
A series of 34 consecutive patients were initially enrolled
in the out patient clinics of a national medical center in
Taipei, Taiwan. Among them, 4 patients who did not
meet the inclusion criteria, 2 patients who were with
poor drugs compliances (missed more than 75% of test
medications), 1 patient with early withdrawal (ALT more
than 5 times of upper normal limits) and 1 patient died
with choking in accident. They were excluded from the
subsequent analyses. Finally, a total of 26 patients
(11 males, aged 60 ± 9 years; 13 with pitavastatin and 13
with atorvastatin) completed the study. The baseline char-
acteristics of the study patients (13 in each group) were
presented in Table 1. There were no differences between
the two treatment groups at baseline.Similar effects of the statin treatment on plasma lipid
profiles and differential on glucose metabolism
The plasma lipid profiles including total cholesterol,
LDL-c and apolipoprotein B levels were significantly and
similarly decreased after 12-week treatment of pitavastatin
or atorvastatin. While the fasting glucose level was not
changed, the homeostasis model of assessment-insulin
resistance (HOMA-IR) index was significantly increased
(from 2.0 ± 1.0 to 3.9 ± 2.8, p = 0.002) after the 12-week
treatment of atorvastatn. There were so much changes in
pitavastatin group (Table 2).
Differential effects of the statin treatment on serum
biomarkers
There were no significant changes in systemic biomarkers
including serum hs-CRP, total NO, interleukin-10, TNF-α,
Table 2 Effects of 4- and 12-week treatment of pitavastatin (PTV) and atorvastatin (ATV) on lipid profiles, systemic biomarkers and endothelial progenitor cells
Baseline 4 weeks 12 weeks PTV# ATV#
PTV ATV P-value PTV ATV P-value PTV ATV P-value P-value P-value
WBC (/cumm) 6223 ± 1790 7184 ± 1563 0.16 6784 ± 2106 7238 ± 1180 0.50 6338 ± 1809 6930 ± 1245 0.34 0.73 0.82
Glucose (mmol/L) 6.98 ± 1.39 6.28 ± 1.04 0.16 7.12 ± 1.71 6.54 ± 1.23 0.39 7.58 ± 2.54 6.54 ± 1.05 0.18 0.71 0.80
HOMA-IR 1.9 ± 1.2 2.0 ± 1.0 0.78 5.2 ± 4.8 3.9 ± 2.8 0.41 0.05 <0.05
hs-CRP (mg/dL) 0.18 ± 0.18 0.35 ± 0.37 0.16 0.17 ± 0.11 0.16 ± 0.19 0.90 0.20 ± 0.20 0.17 ± 0.20 0.88 0.93 0.17
TC (mmol/L) 5.20 ± 0.69 5.24 ± 0.64 0.89 3.73 ± 0.53 3.62 ± 0.36 0.53 3.65 ± 0.52 3.56 ± 0.37 0.58 <0.05 <0.05
TG (mmol/L) 1.53 ± 0.71 1.72 ± 0.59 0.46 1.25 ± 0.58 1.26 ± 0.28 0.94 1.15 ± 0.51 1.22 ± 0.39 0.72 0.26 <0.05
LDL-c (mmol/L) 3.70 ± 0.55 3.82 ± 0.85 0.68 2.12 ± 0.46 2.19 ± 0.45 0.68 2.14 ± 0.33 2.09 ± 0.51 0.76 <0.05 <0.05
HDL-c (mmol/L) 1.25 ± 0.25 1.18 ± 0.19 0.38 1.29 ± 0.33 1.18 ± 0.18 0.32 1.25 ± 0.28 1.19 ± 0.20 0.58 0.92 0.96
NOx (μmol/L) 70.8 ± 42.5 78.5 ± 96.8 0.80 75.3 ± 66.1 80.6 ± 62.9 0.85 79.5 ± 86.1 68.9 ± 46.4 0.71 0.95 0.91
IL-10 (pg/ml) 1.8 ± 1.2 1.5 ± 0.8 0.48 2.1 ± 1.6 2.1 ± 1.4 0.91 2.07 ± 1.6 1.7 ± 1.8 0.57 0.87 0.55
TNF-α (pg/ml) 3.6 ± 1.7 4.0 ± 2.8 0.67 3.3 ± 1.8 4.5 ± 2.8 0.22 2.8 ± 0.8 4.3 ± 3.2 0.12 0.45 0.91
ADMA (μmol/L) 0.61 ± 0.10 0.68 ± 0.10 0.09 0.56 ± 0.12 0.53 ± 0.12 0.55 0.25 <0.05
SDF-1α (pg/ml) 2619.9 ± 640.5 2851.4 ± 669.1 0.38 2673.5 ± 774.6 3043.3 ± 733.5 0.24 2603.6 ± 757.1 3085.5 ± 701.1 0.16 0.98 0.668
VEGF (pg/ml) 74.33 ± 32.26 69.86 ± 31.53 0.72 118.36 ± 50.05 67.65 ± 42.85 0.01 98.65 ± 46.64 74.04 ± 29.33 0.12 <0.05 0.898
EPC level (%)
CD34+KDR+ 0.021 ± 0.015 0.039 ± 0.039 0.16 0.035 ± 0.031 0.029 ± 0.024 0.59 0.054 ± 0.044 0.043 ± 0.029 0.45 <0.05 0.57
Values are mean ± standard deviation. #: Difference between baseline, 4 weeks and 12 weeks of treatment in the same group. WBC: white blood cell; HOMA-IR: Homeostasis model of assessment-insulin resistance;
TC: total cholesterol; TG: Triglyceride; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; hs-CRP: high sensitivity C-reactive protein; NOx: total nitric oxide; IL-10: interleukin-10; TNF-α:
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statin treatment signifcantly reduced serum ADMA con-
centration (from 0.68 ± 0.10 to 0.53 ± 0.12, p = 0.009),
which was not seen by pitavastatin treatment. On the
other hand, the VEGF levels was significantly increased
by the treatment of pitavastatin (from 74.33 ± 32.26 to
98.65 ± 46.64 pg/mL, P < 0.05), which was not seen by
atorvastatin treatment (Table 2).
Differential effects of the statin treatment on
circulating EPCs
The peripheral blood MNCs were gated and granulocytes
by the flow cytometry analysis and the gated MNCs with
dual stained positive cells were shown in the Figure 1.
There were no differences in the number of CD34+KDR+,
CD34+CD133+ or CD133+KDR+ EPC-like cells between
the two treatment groups at baseline (Table 2, Figure 2).
Pitavastatin treatment for 12 weeks significantly in-
creased the number of circulating EPCs (CD34+KDR+)
(0.054 ± 0.044 after treatment v.s. 0.021 ± 0.015% of gated
mononuclear cells at baseline, p < 0.05). There were no
significant changes of CD34+KDR+ EPCs with atorvastatin
treatment (Table 2, Figure 2).
The potential effects of the changes of serum lipid profiles
and biomarkers on the changes of EPCs by pitavastatin
treatment
Further analyses showed that the changes of apolipopro-
tein (Apo) A1 after 12-week treatment were insignificantFigure 1 Representative flow cytometry analysis for quantifying the nin both statin groups (Pitavastatin: 133.8 ± 15.7 mg/dL
to 135.5 ± 14.6 mg/dL, p = 0.54; Atorvastitan: 134.5 ±
19.8 mg/dL to 132.5 ± 16.2 mg/dL, p = 0.50) and no
significant differences between two groups were noted
before and after treatment (p = 0.93 at baseline; p = 0.63
at 12-week). Then, we analyzed the potential association
between the differences of high-density lipoprotein chol-
esterol (HDL-c) or Apo A1 and that of CD34+/KDR+
EPCs or other biomarkers including hs-CRP, NOx, IL-10,
TNF-α, ADMA, SDF-1α and VEGF after 12-week pita-
vastatin treatment. There were no any associations of
the changes of HDL-c or Apo A1 with the changes of
CD34+/KDR+ EPC number in patients with pitavasta-
tin treatment. Therefore, the changes of serum HDL-c
or Apo A1 may be not related to the increment of EPCs
(CD34+/KDR+) number by pitavastatin treatment in this
study.
In vitro study
In the in vitro study, early EPCs cultured from statin-naïve
high-risk patients were treated with pitavastatin (10−7 M)
or atorvastatin (10−7 M) for 24 hours. The adhesive func-
tion of early EPCs was significant enhanced by pitvastatin
(control v.s. atorvastatin v.s. pitavastatin, 47.7 ± 14.0 vs.
51.1 ± 21.0 vs. 61.6 ± 27.8 cells/HPF, p = 0.04, n = 12)
(Figure 3A). In proliferation assay, late EPCs were treated
with pitavastatin or atorvastatin in various concentra-
tions for 24 hours. The proliferation of late EPC was
significantly inhibited by pitavastain with concentrationsumber of circulating endothelial progenitor cells (EPCs).
Figure 3 Pitavastatin significantly increased the adhesion function of early endothelial progenitor cells (EPCs). Early EPCs were pretreated
with pitavastatin and atorvastatin (10−7 M) for 24 hours. The number of adhesion of early EPC was analyzed by fibronectin-adhesion assay (n = 12)
(A). The effects of pitavastatin and atorvastatin on the proliferation of late EPCs, analyzed by MTT assay after treatment with different doses
of statins for 24 hours (B), migration (C) and capillary tube formation (D). Data are presented as mean ± SD in each experiment; n = 4.
*: p < 0.05 compared with control.
Figure 2 Percentage of stained dual-positive endothelial progenitor cells (EPCs) of gated mononuclear cells analyzed by flow cytometry.
There are no differences of (A) CD34+CD133+ EPCs and (B) CD133+KDR+ EPCs between pitavastatin and atorvastatin groups. (C) The levels of
circulating CD34+KDR+ EPCs are significantly increased after 12 week treatment with pitavastatin. *: p < 0.05 compared with baseline.
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group (Figure 3B). Then, we chose the concentrations of
10−7 M of both statins in the in vitro studies. In migra-
tion assay, late EPCs treated with pitavastatin but not
atorvastatin for 24 hours showed significant enhance-
ment of migration ability (136.7 ± 14.7 v.s. 91.0 ± 20.7
number/HPF, p < 0.05) (Figure 3C). Moreover, in the
in vitro angiogenesis assay, pitavastatin (10−7 M) but not
atorvastatin significantly increased capillary-like patterns in
high-power fields as compared with controls (161.5 ± 29.5
v.s. 123.1 ± 25.1% of control, p = 0.032) (Figure 3D).
Finally, to elucidate the potential mechanisms of the
effects of statins, we examined the protein expression of
total form and phosphorylated eNOS in late EPCs after
co-incubated with pitavastatin or atorvastatin (10−7 M)
for 24 hours. Both statins significantly enhanced total form
eNOS protein expressions (Figure 4A). However, only pita-
vastatin increased the ratio of phosphorylated eNOS over
total eNOS expression (0.65 ± 0.03 vs. 0.51 ± 0.02, p < 0.05,
n = 6) (Figure 4B), suggesting the direct effects of pitavasta-
tin on EPC eNOS activation. Futhermore, only pitavastatin
(10−7 M) increased the VEGF expression (2.14 ± 0.33 vs.
0.90 ± 0.11, p < 0.05, n = 6) (Figure 4C), suggesting the
direct effects of pitavastatin on VEGF expression in early
EPCs.
Discussion
The cardinal findings of our study included that (1) while
the treatment of pitavastatin or atorvastatin in an ordinary
dose for 12 weeks significantly reduced serum total choles-
terol, LDL-c and apolipoprotein B to a similar extent, only
pitavastatin significantly increased serum VEGF levels and
the number of circulating EPCs in high risk patients;Figure 4 Pitavastatin increased the endothelial nitric oxide synthase (
in human endothelial progenitor cells (EPCs). Late EPCs were pretreated
pitavastatin and atorvastatin increased significantly total form of eNOS activ
over total eNOS significantly increased only in late EPCs after co-incubated wi
of VEGF in early EPCs analyzed by Western blotting (C). *: P < 0.05 was consid(2) pitavasatin directly enhanced in vitro adhesion, migra-
tion, and tube formation with increased eNOS phosphor-
ylation and VEGF expression in early or late EPCs from
the patients; (3) atorvastatin treatment significantly re-
duced serum ADMA levels, a nature inhibitor of eNOS.
Atorvastatin indirectly increased in vitro eNOS expres-
sion without altering eNOS phosphorylation and the
function of EPCs. Taken the above together, long-term
treatment with an ordinary dose of pitavastatin may in-
crease circulating EPC number, which might be partially
related to its direct effects on eNOS activation in EPCs
and indirect effects by elevation of systemic VEGF. On
the other hand, atorvastatin treatment did not increase
circulating EPC number though did reduce serum ADMA
levels. Further, atorvastatin did not alter eNOS expression
and in vitro EPC function. Accordingly, in terms of chronic
treatment with an ordinary dose, different statins such as
pitavastatin and atorvastatin may have different effects on
circulating EPCs. Our findings suggest that the vascular
protection indicated by EPCs may vary with different sta-
tins, which might be not a class effect of statins.
It was previously shown that short-term treatment
(less than 4 ~ 8 weeks) of some statins in a high dose
could promote EPC mobilization from the bone marrow
and ameliorate EPCs’ function, leading to vascular pro-
tection in different clinical conditions [12-15,17,20]. In
the current study, our findings provide additional clinical
evidence for the beneficial effects of long-term (more
than 10 weeks) pitavastatin treatment in an ordinary
dose on EPCs. The beneficial effects may be selective
with pitavastatin and independent to lipid lowering since
the reduction of serum cholesterol level was similar by
both statins. Our findings are partially in line with theeNOS) and vascular endothelial growth factor (VEGF) expression
with pitavastatin and atorvastatin (10−7 M) for 24 hours. Both of
ation analyzed by Western blotting (A). Ratio of phosphorylated eNOS
th pitavasatin (B). Pitavastatin (10−7 M) increased significantly expression
ered significant.
Figure 5 Schematic representation of the possible mechanism
of effects of pitavastatin and atorvastatin on endothelial
progenitor cells (EPCs). Atorvastatin decreased serum asymmetric
dimethylarginine (ADMA) and pitavastatin increased serum vascular
endothelial growth factor (VEGF), both increasing the expression of
total form endothelial nitric oxide synthase (eNOS) in late EPCs. Only
pitavastatin could increase circulating EPCs number and function via
enhancing eNOS activity.
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statin (10 mg/day for 4 weeks) but not ezetimibe in-
creased the number of EPCs in 10 patients with chronic
heart failure [17]. Taken together, though the mecha-
nisms have not been completely clarified, either pitavas-
tatin or simvastatin may have the pleiotropic beneficial
effects particularlly on circulating EPCs in different clinical
settings.
Several putative mechanisms of statin-induced EPCs
mobilization were illustrated via increased endothelial
NO availability, serum VEGF, receptor activator of NF-
kappaB ligand (RANKL) and activation of matrix metal-
loproteinase (MMP)-2 and −9 [21-25]. The increase in
MMP activity could result in degradation of the extra-
cellular matrix and reduce cellular attachment within
the bone marrow niches, leading to the mobilization
of EPCs into circulation. In addition, HDL-c is also
suggested as an determinant of endothelial function and
associated with EPCs number in hypercholesterolemia
patients [26]. Pitavastatin was considered as a statin that
could significantly increase HDL-c in patients with meta-
bolic syndrome or type 2 diabetes mellitus [27]. However,
there was no significant effect of the changes of serum
HDL-c on the changes of circulating EPCs by pitavastatin
in our study. Whereas, it was previously shown that
pitavastatin treatment for 4 weeks did not alter the EPC
promoting efficacy in the chronic smokers. Thus, it is
probable that short-term treatment with pitavastatin was
not long enough to restore the circulating EPCs count
[28]. However, in the present study, both serum VEGF
level and the number of circulating EPCs were signifi-
cantly increased after 12-week treatment of pitavastatin
but not atorvasatin. In previous animal study, pitavastatin
had been shown to increase serum VEGF levels in mur-
ine with ischemic limb [29]. Moreover, VEGF is a known
EPC mitogen, which increased the proliferation rate of
EPCs as well as the activities. After EPCs mobilization
from bone marrow, reduced VEGF levels may result in
the slow growth and suppressed the activation of circu-
lating EPCs. In vitro cellular studies and animal results
suggested that VEGF gene transfer would augment EPC
proliferation, adhesion, incorporation into endothelial cell
monolayers, and in vivo neovascularization [30]. In the
contrast, recent report shows atorvastatin in ordinary dose
(10 mg per day) would decrease serum concentration of
VEGF in patients with type 2 diabetes [31]. In addition,
direct effects of pitavastatin on EPC eNOS activation were
found in our in vitro study. The key role of eNOS phos-
phorylation for a statin in promoting ischemia-induced
angiogenesis had been demonstrated previously without
accelerating tumor-associated angiogenesis [32,33]. Taken
together, it seems that beneficial effects of pitavastatin on
circulating EPCs might be related to the increase in serum
VEGF and the direct effects on eNOS activation (Figure 5).In the present study, pitavastatin treatment mainly
increased the number of CD34+KDR+ EPCs. The defin-
ition of EPCs, as the biomarkers for cardiovascular disease,
remains an unresolved question [34,35]. The scientific
foundation of EPCs is based on the use of isolated
hematopoietic CD34+ cells that were shown to give rise to
endothelial marker expressing cells [8]. Because CD34 is
also expressed on matured endothelial cells, the more im-
mature marker CD133 has been used to select for putative
EPCs [36]. Based on the definition of EPCs, the minimal
antigenic profile should include at least 1 marker of stem-
ness/immaturity (usually CD34 and/or CD133), plus at
least 1 marker of endothelial commitment (usually KDR).
Circulating EPCs have been defined as CD34+KDR+ by
several investigators, as it was confirmed that this pheno-
type rather than others identifies cells capable of stimulat-
ing angiogenesis in vivo [37]. It was recently reported that
CD34+KDR+ cells showed better relationships with CHD
and response to statin therapy if restricted to the dimin-
ished CD45 gate [38]. Indeed, though there was no control
group in this study, the number (0.021 ± 0.015%) of circu-
lating CD34+KDR+ EPCs of our patients was much lower
than that (1.2 ± 1.0%) of the local healthy subjects in simi-
lar age, and higher than that (0.007 ± 0.007%) in another
group of age-matched patients with severe coronary artery
disease in our previous study [39,40]. Accordingly, the
CD34+KDR+ EPCs may be the most representative one in
all subsets of circulating EPCs in the present study.
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linked to the risk for atherosclerosis. In the current
study, atorvastatin treatment significantly decreased serum
ADMA level. It is in line with the previous findings that
atorvastatin treatment reduced serum ADMA levels in pa-
tients with ischemic stroke [41]. However, in our study, the
effects on serum ADMA level were not translated to the
beneficial effects on circulating EPCs. Indeed, in previous
studies, while improving endothelial function and clinical
outcomes, atorvastatin or simvastatin treatment did not
alter plasma ADMA levels [42,43]. Accordingly, the clinical
beneficial effects of statins may be not related to the
alteration of serum ADMA. Future study should clarify the
exact role of ADMA in the modification of EPCs.
There are some limitations of the study. Given the
limited patient number and limited study duration, we
can not exclude the possibility that atorvastatin treatmet
may improve EPCs with a larger dose for a longer period
of duration. Besides, there were predominantly patients
with T2DM and there were no clinical outcomes shown in
the study. Thus, the current findings should be viewed for
concept proofing rather than conclusive. Future study is
required to determine if the beneficial effects of statin on
circulating EPCs could be translated to the benefit in some
specific clinical outcomes in the general cohort.
In conclusion, while both similarly reduced plasma
lipids, pitavastatin treatment in an ordinary dose, rather
than atorvastatin treatment, increased serum VFGF level
and circulating CD34+KDR+ EPCs number. Besides,
pitavastatin but not atorvastatin activated eNOS and
improve in vitro function of EPCs. Though still waiting
for further confirmation, our findings did support the
concept that vascular pleiotropic protection effects could
vary with different statins, which might not be a class ef-
fect in clinical settings. Given the increasing importance
of circulating EPCs for vascular repair in patients with
severe atherosclerosis and T2DM, our fiindings may also
provide a potential rationale for clinical statin treatment
in some particular conditions where the improvement of
circulating EPCs should be taken into consideration.
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